BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer

BeiGene Ltd BGNE has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastatic nasopharyngeal cancer, a rare type of head and neck cancer.
The trial demonstrated a statistically significant improvement (primary endpoint) in progression-free survival compared to chemotherapy alone at the interim analysis, as recommended by an independent data monitoring committee.
The safety profile of tislelizumab was consistent with its known risks, with no new safety signals identified with the addition of chemotherapy.
BeiGene plans to discuss these data with health authorities and present data at an upcoming medical conference.
Price Action: BGNE shares closed at $344.15 on Thursday.